Alzheimer's & Dementia

Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills. Alzheimer’s is the most common cause of dementia among older adults. Dementia is the loss of cognitive functioning—thinking, remembering, and reasoning—and behavioral abilities to such an extent that it interferes with a person’s daily life and activities.

GLP-1 Receptor Agonists in Alzheimer’s Disease: Emerging Off-Label Neuroprotective Potential

GLP-1 receptor agonists show strong preclinical neuroprotective potential in Alzheimer’s disease through effects on insulin signaling, neuroinflammation, amyloid, tau, and brain metabolism. Human evidence remains mixed, with observational studies suggesting lower dementia risk but randomized trials yet to demonstrate a clinically meaningful disease-modifying benefit.

Alzheimer’s Disease and Gingko Biloba

Aromatherapy for Dementia

Mixed Dementia Prevention and Treatment

What are Amyloid Plaques?

Childhood Dementia Causes

Biomarkers for Alzheimer's Disease

Alzheimer's Disease Symptoms

Can Happiness Protect You from Dementia?

Inflammation and Alzheimer's Disease

Bright Light Therapy and Dementia

Does Herpesvirus Cause Alzheimer's?

See more featured articles »

Do Antioxidants Benefit Patients with Alzheimer’s and Parkinson’s?

Dancing Through Dementia: How Movement Aids Memory and Mood

Migraines and Dementia

Parkinson's Compared to Dementia with Lewy Bodies (DLB)

Pollution and Alzheimer's

AAM - Air pollution and Alzheimer's

Mixed Dementia Symptoms and Diagnosis

AAM - Genetics of Alzheimer's

Designing Dementia-Friendly Environments

Antibody Research and Alzheimer’s Disease

Alzheimer's Disease and Sleep Disruption

Alzheimer's Disease Prevention

Dementia Diagnosis

Alzheimer’s Disease and Calcium Supplements

Alzheimer’s Disease | Definition, Causes, Diagnosis & Treatment

Diet and Alzheimer's Disease

Integrated PET/MR for Alzheimer’s Disease

Stress and Alzheimer's Disease

What Causes Dementia?

Dementia with Lewy Bodies

What is Dementia?

Dementia Prevention

Types of Alzheimer's Disease

What is Mixed Dementia?

Differences Between Alzheimer's and Dementia

Alzheimer's Disease Diagnosis

Gender and Alzheimer’s Risk

Omega-3 and Alzheimer’s Disease

Alzheimer's and Veganism

Amyloid Cascade Hypothesis

Antidepressants and Dementia: Is There a Link?

Coconut Oil and Dementia

Does Type 2 Diabetes Increase the Risk of Alzheimer’s Disease?

Stem Cell Therapy for Alzheimer's

Dementia Treatment

Childhood Dementia Signs and Symptoms

AAM - The Search for a Cure to Alzheimer's

Alzheimer's Disease Epidemiology

Is Alzheimer's Disease Transmissible?

Transcutaneous Electrical Nerve Stimulation for Dementia

Can Statins Protect Against Alzheimer’s Disease?

Alzheimer's Disease Treatments

Alzheimer's Disease Causes

Does Depression and Anxiety Increase the Risk of Dementia?

Alzheimer's Disease Questions

Dementia Symptoms

Mythbusting: Misconceptions in Dementia

Alzheimer’s tangles and plaques: what’s the difference?

Alzheimer's Disease and the Microbiome

Latest Alzheimer's & Dementia News and Research

Blood proteins may help monitor Alzheimer’s treatment response

Patients with early symptoms of Alzheimer's disease may be prescribed anti-amyloid therapy, which can help clear the sticky clumps of amyloid protein in the brain that characterize Alzheimer's.

25 Sep 2026

Mount Sinai researchers discover how Alzheimer's gene damages blood vessels

Mount Sinai researchers have identified how APOE4, the strongest genetic risk factor for Alzheimer's disease, damages the brain's blood vessels and promotes the buildup of abnormal proteins linked to neurodegenerative disease.

24 Sep 2026

Five research teams secure funding for frontotemporal dementia studies

The Kissick Family Foundation, in partnership with the Milken Institute Science Philanthropy's Accelerator for Research and Collaboration (SPARC), today announced five research teams selected to receive a total of $2.5 million through the third funding cycle of the Kissick Family Foundation Frontotemporal Dementia (FTD) Grant Program.

24 Sep 2026

Chronic stress and social support affect how cognitive abilities change with age

Chronic stress and perceived social support may play a role in how memory and thinking abilities change with age, according to a new study led by researchers at Wake Forest University School of Medicine.

24 Sep 2026

Lund University gets $19.4 million grant for Alzheimer’s blood test

Alzheimer’s researcher Sebastian Palmqvist has been awarded USD 19.4 million (SEK 190 million) from the US National Institutes of Health (NIH), through its National Institute on Aging (NIA).

24 Sep 2026

Frailty linked to greater cognitive impairment risk in men with chronic kidney disease

New research from the University of Colorado Anschutz Department of Medicine is shedding light on how women and men with chronic kidney disease (CKD) may fare differently as they age and their disease progresses.

23 Sep 2026

Transient ischemic attacks linked to increased long-term dementia risk

Having a transient ischemic attack (TIA) is associated with an increased risk of developing dementia, according to a new study published September 23, 2026, in Neurology, the medical journal of the American Academy of Neurology.

23 Sep 2026

PsychAD studies map molecular mechanisms across major brain disorders

Research led by Mount Sinai scientists within the PsychAD Consortium, a large-scale, multidisciplinary initiative launched in 2019 with support from the National Institute on Aging (NIA), is featured in a landmark collection of nine papers published across the Nature family of journals that maps the molecular mechanisms underlying Alzheimer's disease, Parkinson's disease, schizophrenia, and other brain disorders.

23 Sep 2026

Menopause leaves a blood protein signature linked to brain aging and Alzheimer’s risk

Researchers identified a 16-protein blood signature associated with menopause that tracked more strongly with reproductive hormones than chronological age and was largely replicated in an independent UK Biobank cohort. Higher menopause proteomic scores were also associated with less favorable proteomic aging estimates and poorer cognitive outcomes in older women, including incident Alzheimer’s dementia, although the observational evidence does not establish causality.

23 Sep 2026

Experimental drug reverses multiple sclerosis damage in mouse model

A drug developed by a UVA Health scientist has not only stopped but reversed paralysis and vision loss in a mouse model of multiple sclerosis.

23 Sep 2026

New 3D lipid atlas maps the chemistry of mouse brains

The brain is often described in terms of cells and wiring. However, much of it is made of lipids that form the membranes of neurons, wrap nerve fibers with myelin, and help brain cells send and receive signals.

23 Sep 2026

People with dementia can participate in research without experiencing significant burden

A multidisciplinary study conducted at the University of Eastern Finland has shown that people with dementia and their caregivers can participate in demanding research without experiencing a significant burden.

23 Sep 2026

C-Path awards $1.7 million to advance five drug development projects

Critical Path Institute (C-Path) today announced that its Translational Therapeutics Accelerator has awarded $1,699,500 through five Bridging Research and Innovation in Drug Development Grants (BRIDGe).

22 Sep 2026

Loneliness and social isolation cost people years of healthy life

The numbers paint a grim picture. Roughly half of all U.S. adults are lonely, according to a 2023 report, and nearly as many feel socially isolated.

22 Sep 2026

Low spinal bone density may predict faster brain aging

Researchers at Johns Hopkins University found that lower bone mineral density in the spine was associated with faster cognitive decline and accelerated age-related white matter injury, according to a new study published today in Radiology, a journal of the Radiological Society of North America.

22 Sep 2026

KAIST researchers develop NUDGE technology to steer cell fate

Which genes need to be controlled to guide a stem cell toward a desired cell type, or to modulate an immune cell's inflammatory response? A Korean research team has developed a general-purpose computational framework that identifies the key targets needed to steer a cell toward a desired state with a single temporary intervention, without permanently altering its genes.

22 Sep 2026

Brain Health WA resource aims to reduce dementia risk

With Western Australia projected to record the nation's fastest growth in dementia cases, a new Curtin University-led resource aims to help people protect their brain health and reduce their risk.

22 Sep 2026

Galimedix establishes Scientific Advisory Board for Alzheimer’s disease to guide development of novel oral drug candidate, GAL-101

Galimedix Therapeutics, Inc., a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious brain and eye diseases, today announced the establishment of a dedicated Alzheimer's Disease Scientific Advisory Board (SAB).

From Galimedix Therapeutics, INC. 22 Sep 2026

High cognitive impairment rates among homeless people demand radical policy change

Cognitive impairment is a prevalent but often unaddressed factor in chronic homelessness, and it must be addressed to help reduce homelessness, argues the author of a commentary published in CMAJ

21 Sep 2026